The firm saw an improvement in progression-free survival for patients on the ivonescimab regimen and a trend toward improved overall survival.

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient ...

Christopher Danes, PhD, discusses a study exploring the differences in priorities for patients and their caregivers when undergoing treatment for non–small cell lung cancer.

Survival rates among breast cancer patients whose cancer is detected before it spreads are high, between 86% and 89%. Yet if the cancer is detected after the cancer cells have migrated, that number ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...

Summit Therapeutics' Phase 3 trial met the primary goal in lung cancer, showing significant PFS benefit with ivonescimab plus ...

(SMMT) stock rises as its lung cancer drug ivonescimab with chemotherapy hit the main goal in a Phase 3 trial for lung cancer ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...